MGMT promoter methylation status is determined in routine formalin-fixed, paraffin-embedded glioma tumor specimens, usually by bisulfide treatment of tumor DNA followed by DNA sequencing (Weller et al., 2010). The gene discussed is MGMT; the disease is central nervous system cancer.